<DOC>
	<DOCNO>NCT00984581</DOCNO>
	<brief_summary>To assess safety toleration , systemic exposure anti-scarring potential intradermal avotermin ( Juvista ) young female .</brief_summary>
	<brief_title>Safety Efficacy Study Avotermin ( Juvista ) Female Subjects</brief_title>
	<detailed_description>Subjects receive two 1cm incision upper , inner aspect arm ( four wound per subject ) . On Day 0 subject receive intradermal Juvista concentration 50ng/100ul one incision site Arm 1 5ng/100ul one incision site Arm 2 . The incision sit injected placebo . Following injection , 1cm incision wound make site . On Day 1 subject re-injected 100ul/cm intradermal Juvista placebo side wound ( 200ul per incision ) concentration Day 0 ( 50 5ng/100ul ) . At month 6 incision site excise histological analysis excision site inject Juvista . Both site Arm 1 receive 50ng/100ul/linear cm wound margin sit Arm 2 receive 5ng/100ul/linear cm wound margin . No excision sit receive placebo . The appearance excision scar assess 2 , 4 6 month heal i.e month 8 , 10 12 study .</detailed_description>
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Clinically healthy , female subject age 1845 year Weight 40150 kg BMI within permitted range height use Quetelet 's index ( 1535 kg/m ( square ) ) . Weight ( kg ) /height ( square ) ( ) Subjects use appropriate nonpharmaceutical method contraception likely become pregnant duration trial Subjects history evidence hypertrophic keloid scar tattoos previous scar area biopsied Subjects personal history bleed disorder AfroCaribbean subject exclude increased susceptibility hypertrophic keloid scar Subjects skin disorder chronic currently active investigator considers adversely affect heal acute wound involve area examine trial Subjects clinically significant medical condition would impair wound heal include significant rheumatoid arthritis , chronic renal impairment , significant hepatic impairment , inadequately uncontrolled digestive heart failure , active malignancy , immunosuppressive , radiation chemotherapy within last three month , history radiotherapy arm diabetes mellitus Subjects history clinically significant drug hypersensitivity lignocaine allergy surgical dressing use trial Subjects clinically significant abnormality follow review pretrial laboratory data physical examination Subjects taking , take , investigational drug , long term oral , topical inhale corticosteroid therapy , HRT , oral contraceptive pill , pharmaceutical method contraception anticoagulant drug thirty day prior Day 0 Subjects evidence drug abuse Subjects know serum hepatitis carrier hepatitis B surface antigen hepatitis C antibody . Subjects previous vaccination hepatitis B exclude per se Subjects carrier hepatitis B core antibody show le 10 unit per litre AntiHBs Subjects previously positive result test HIV antibody , admit belong high risk group subject point positive pregnancy test Subjects pregnant become pregnant trial In opinion investigator , subject likely complete trial ever reason</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cicatrix</keyword>
	<keyword>Scar</keyword>
	<keyword>Wound heal</keyword>
	<keyword>Avotermin</keyword>
	<keyword>TGF beta 3</keyword>
	<keyword>Juvista</keyword>
	<keyword>RN1001</keyword>
</DOC>